Benzinga··NaHemab Therapeutics Prices $346.7M IPO as Blood Disorder Biotech Debuts on Nasdaq
Hemab Therapeutics raised $346.7M in upsized IPO, pricing 19.3M shares at $18 with full underwriter exercise.
COAGIPOclinical-stage
C
$COAG
1 article found1 positive
0 negative
0 neutral